Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

trastuzumab

- PMLiVE

Positive first-line phase 3 results for Tecentriq

Hopes to extend use in bladder cancer

- PMLiVE

Roche reveals yet another Spark takeover delay

Are concerns about haemophilia dominance the cause?

- PMLiVE

Lilly boosted by survival data for key growth drug Verzenio

Chases Pfizer's Ibrance

- PMLiVE

Keytruda scores in neoadjuvant triple negative breast cancer combo

Tecentriq still in pole position

Roche Basel Switzerland

New products help lift Roche outlook despite biosimilar onslaught

Two new cancer therapies approved in Q2

- PMLiVE

Kisqali combination follows Verzenio onto Cancer Drugs Fund

Drug must prove its value via managed access route

- PMLiVE

Genentech taps into Sosei Heptares GPCR expertise with $1bn alliance

Targeting largest family of proteins in cell membranes

Battling breast cancer with precision medicine (Part 2)

Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Blue Latitude Health

Battling breast cancer with precision medicine (Part 1)

Laura Holmes Haddad is a breast cancer survivor. She made the incredibly brave decision to participate in a PARP inhibitor precision medicine trial. Here, the author and precision medicine advocate...

Blue Latitude Health

Roche - Basel

Roche’s Polivy gets FDA okay for lymphoma chemo-immunotherapy

First-in-class antibody drug conjugate

Roche Basel Switzerland

Roche/GE’s digital medicine alliance bears first fruit

While new player enters liquid biopsy market

Novartis day

FDA clears Novartis’ new breast cancer drug Piqray

Blockbuster potential for PI3K drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links